National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 82387-82388 [2023-25937]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 225 / Friday, November 24, 2023 / Notices
Dated: November 17, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–25940 Filed 11–22–23; 8:45 am]
Center for Scientific Review; Notice of
Closed Meeting
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Avenir
Award Program for Genetics or Epigenetics of
Substance Use Disorders.
Date: February 13–14, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, Bethesda, MD
20892, (301) 827–4471, ramadanir@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: November 17, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–25938 Filed 11–22–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
21:46 Nov 22, 2023
Jkt 262001
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Drug Development and Molecular
Pharmacology—A.
Date: December 5, 2023.
Time: 3:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bidyottam Mittra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20894, (301) 435–4057,
bidyottam.mittra@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 17, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25884 Filed 11–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
82387
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Acquired Immunodeficiency
Syndrome Research Study Section Acquired
Immunodeficiency Syndrome Research
Study Section (AIDS).
Date: December 13, 2023.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G21B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G21B, Bethesda, MD
20852, (240) 669–5035, robert.unfer@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 17, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–25939 Filed 11–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
E:\FR\FM\24NON1.SGM
24NON1
82388
Federal Register / Vol. 88, No. 225 / Friday, November 24, 2023 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Contract Review.
Date: December 13, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Michael P. Reilly, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 208–Z,
Bethesda, MD 20892, (301) 827–7975,
reillymp@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 20, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25937 Filed 11–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities Comment Request
ddrumheller on DSK120RN23PROD with NOTICES1
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: National Substance
Use and Mental Health Services Survey
(N–SUMHSS) (OMB No. 0930–0386)—
Revision
Under section 505 of the Public
Health Service Act (42 U.S.C. 290aa–4),
SAMHSA is required to conduct annual
collection of data on substance use and
mental health. Selected information
collected from the N–SUMHSS is also
published on SAMHSA’s
FindTreatment.gov for persons seeking
treatment for mental and substance use
disorders in the United States.
VerDate Sep<11>2014
21:46 Nov 22, 2023
Jkt 262001
FindTreatment.gov is authorized by the
21st Century Cures Act (Pub. L. 114–
255, section 9006; 42 U.S.C. 290bb–
36d).
In 2021, SAMHSA combined the
National Survey of Substance Abuse
Treatment Services (N–SSATS) and the
National Mental Health Services Survey
(N–MHSS) into the N–SUMHSS to
reduce the burden on facilities offering
both substance use and mental health
services, optimize government resources
to collect data, and enhance the quality
of data collected on the treatment
facilities.
The N–SUMHSS is the most
comprehensive national source of data
on substance use and mental health
treatment facilities. On an annual basis,
the N–SUMHSS collects information on
the facility location, characteristics, and
utilization of substance use and mental
health treatment services. The survey
also collects client counts on
individuals receiving services at these
facilities. There is an increasing need to
collect and maintain data on current
and accurate numbers of clients in
treatment at the local level for
communities to assess capacity and
estimate resource requirements. This
information on substance use and
mental health services has assisted with
communities to better respond to life
changing events, (i.e. hurricane) and
plan for service demands in the event of
a natural disaster (i.e. earthquakes).
SAMHSA also maintains the
Inventory of Substance Use and Mental
Health Treatment Facilities (I–TF)
(previously known as the Inventory of
Behavioral Health Services [I–BHS]).
The I–TF is a master list of all known
substance use and mental health
treatment facilities in the United States.
It also serves as the universe population
for the N–SUMHSS.
SAMHSA is requesting OMB approval
of revisions to the N–SUMHSS and I–TF
related data collections, to include
changes to the following instruments:
N–SUMHSS Questionnaire
• Q1a: added to clarify if facilities
reported providing mental health
treatment services in Q1 also provide
substance use treatment services, to
help respondents understand how to
respond accurately and ensure
appropriate survey module(s) are
completed.
• A1a: add the word ‘‘health’’ to
clarify and improve survey item
accuracy.
• A8a. and QA9: add ‘‘for opioid use
disorder’’ and ‘‘for alcohol use disorder’’
in the existing question to clarify clients
using MAT for specific substance use
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
disorder and to improve survey item
accuracy.
• B7a: add the following new survey
response options to the existing
question to improve survey response
option comprehensiveness:
Æ Add ‘‘Prochlorperazine’’ to the
existing list of first-generation
antipsychotics.
Æ Add ‘‘Inhalation’’ and ‘‘Don’t
Know’’ to the existing route of
administration options for firstgeneration antipsychotics.
Æ Add new response options of
‘‘Sublingual,’’ ‘‘Transdermal,’’ and
‘‘Don’t Know’’ to the existing route of
administration options for secondgeneration antipsychotics.
Æ Add ‘‘Other first-generation
antipsychotic #1 Specify, #2 Specify,
and #3 Specify’’ and ‘‘Other secondgeneration antipsychotic #1 Specify, #2
Specify, and #3 Specify’’ to the existing
list of first-generation and secondgeneration antipsychotics.
• B11: add the word ‘‘currently’’ to
the question to improve survey item
accuracy. Change the word ‘‘persons’’ to
‘‘clients’’ to increase survey item
consistency between survey modules.
• B19: update the full title and add
the acronyms ‘‘CSBG’’ and ‘‘MHBG’’ of
the two existing Federal grants to
improve survey item accuracy. Add
‘‘other’’ to clarify and help respondents
better comprehend what is being asked.
• C6a., C7a., C8., C8a: Update the
locator reference from the ‘‘Behavioral
Health Treatment Services Locator’’ to
FindTreatment.gov and the reference
years associated with reporting client
count data.
N–SUMHSS Between Cycle
Questionnaire
Since the Mini N–SUMHSS is a
subset of the N–SUMHSS, all proposed
changes to the N–SUMHSS (listed
above) apply to the Mini N–SUMHSS.
N–SUMHSS VA Supplement
SAMHSA proposes a new N–
SUMHSS VA Supplement to collect
information annually on suicide-related
services, standardized suicide screening
and evaluation tools, clients at high risk
of suicide, referrals and follow-ups from
VA substance use and mental health
facilities. VA facilities providing only
substance use treatment service will
answer 7 questions (Attachment C). VA
facilities providing only mental health
treatment service will answer 12
questions (Attachment D). VA facilities
providing both substance use and
mental health treatment services will
answer 19 questions.
E:\FR\FM\24NON1.SGM
24NON1
]]>Agencies
[Federal Register Volume 88, Number 225 (Friday, November 24, 2023)]
[Notices]
[Pages 82387-82388]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25937]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which
[[Page 82388]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Contract Review.
Date: December 13, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael P. Reilly, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7975,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: November 20, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-25937 Filed 11-22-23; 8:45 am]
BILLING CODE 4140-01-P
